全文获取类型
收费全文 | 222篇 |
免费 | 4篇 |
专业分类
基础医学 | 4篇 |
临床医学 | 48篇 |
内科学 | 153篇 |
皮肤病学 | 1篇 |
神经病学 | 2篇 |
外科学 | 12篇 |
预防医学 | 2篇 |
药学 | 3篇 |
肿瘤学 | 1篇 |
出版年
2023年 | 1篇 |
2021年 | 5篇 |
2020年 | 2篇 |
2019年 | 3篇 |
2018年 | 1篇 |
2016年 | 7篇 |
2015年 | 5篇 |
2014年 | 12篇 |
2013年 | 18篇 |
2012年 | 15篇 |
2011年 | 14篇 |
2010年 | 14篇 |
2009年 | 19篇 |
2008年 | 13篇 |
2007年 | 18篇 |
2006年 | 7篇 |
2005年 | 19篇 |
2004年 | 18篇 |
2003年 | 10篇 |
2002年 | 2篇 |
2001年 | 6篇 |
2000年 | 4篇 |
1999年 | 6篇 |
1998年 | 3篇 |
1996年 | 1篇 |
1992年 | 2篇 |
1990年 | 1篇 |
排序方式: 共有226条查询结果,搜索用时 218 毫秒
1.
Notfall + Rettungsmedizin - Das akute Koronarsyndrom ist der häufigste Grund für einen Rettungsdiensteinsatz in Deutschland. So resultieren in etwa 20–25 % aller Einsätze... 相似文献
2.
3.
Prof. Dr. U. Zeymer 《Gef?sschirurgie》2013,18(3):231-240
Antithrombotic treatment is one of the cornerstones of acute and long-term therapy of patients with acute coronary syndromes (ACS). For this purpose antiplatelet as well as antithrombin agents are used. These drugs can reduce mortality and recurrent ischemic events but may increase bleeding complications. Therefore, simple and easy to use antithrombotic regimens are desirable especially in the prehospital phase to reduce complications associated with overdosing and underdosing. Aspirin is well established for all patients with ACS. In addition an adenosine diphosphate (ADP) receptor blocker should be given in acute therapy and over 12 months after ACS. The value of thrombin inhibitors has been documented mainly for the acute phase. This article summarizes currently available data and recommendations for prehospital antithrombotic therapy in patients with ACS. 相似文献
4.
Giuseppe De Luca MD C. Michael Gibson MD Kurt Huber MD Uwe Zeymer MD Dariusz Dudek MD Donald Cutlip MD Francesco Bellandi MD Marko Noc MD Ayse Emre MD Simona Zorman MD H. Mesquita Gabriel MD Mauro Maioli MD Tomasz Rakowski MD Mariann Gyngysi MD Arnoud W.J. van't Hof MD 《American heart journal》2009,158(3):416-421
5.
Giugliano RP Roe MT Harrington RA Gibson CM Zeymer U Van de Werf F Baran KW Hobbach HP Woodlief LH Hannan KL Greenberg S Miller J Kitt MM Strony J McCabe CH Braunwald E Califf RM;INTEGRITI Investigators 《Journal of the American College of Cardiology》2003,41(8):1251-1260
OBJECTIVES: The goal of this study was to evaluate combinations of eptifibatide with reduced-dose tenecteplase (TNK) in ST-elevation myocardial infarction (STEMI). BACKGROUND: Glycoprotein IIb/IIIa inhibitors enhance thrombolysis. The role of combination therapy in clinical practice remains to be established. METHODS: Patients (n = 438) with STEMI <6 h were enrolled. In dose-finding, 189 patients were randomized to different combinations of double-bolus eptifibatide and reduced-dose TNK. In dose-confirmation, 249 patients were randomized 1:1 to eptifibatide 180 microg/kg bolus, 2 microg/kg/min infusion, and 180 microg/kg bolus 10 min later (180/2/180) plus half-dose TNK (0.27 mg/kg) or standard-dose (0.53 mg/kg) TNK monotherapy. All patients received aspirin and unfractionated heparin (60 U/kg bolus; infusion 7 U/kg/h [combination], 12 U/kg/h [monotherapy]). The primary end point was Thrombolysis In Myocardial Infarction (TIMI) grade 3 epicardial flow at 60 min. RESULTS: In dose-finding, TIMI grade 3 flow rates were similar across groups (64% to 68%). Arterial patency was highest for eptifibatide 180/2/180 plus half-dose TNK (96%, p = 0.02 vs. eptifibatide 180/2/90 plus half-dose TNK). In dose-confirmation, this combination, compared with TNK monotherapy, tended to achieve more TIMI 3 flow (59% vs. 49%, p = 0.15), arterial patency (85% vs. 77%, p = 0.17), and ST-segment resolution (median 71% vs. 61%, p = 0.08) but was associated with more major hemorrhage (7.6% vs. 2.5%, p = 0.14) and transfusions (13.4% vs. 4.2%, p = 0.02). Intracranial hemorrhage occurred in 1.0%, 0.6%, and 1.7% of patients treated with any combination, eptifibatide 180/2/180 and half-dose TNK, and TNK monotherapy, respectively. CONCLUSIONS: Double-bolus eptifibatide (180/2/180) plus half-dose TNK tended to improve angiographic flow and ST-segment resolution compared with TNK monotherapy but was associated with more transfusions and non-cerebral bleeding. Further study is needed before this combination can be recommended for general use. 相似文献
6.
Cercek B Shah PK Noc M Zahger D Zeymer U Matetzky S Maurer G Mahrer P;AZACS Investigators 《Lancet》2003,361(9360):809-813
7.
Embolic protection devices for carotid artery stenting: better results than stenting without protection? 总被引:11,自引:0,他引:11
Ralf Zahn Bernd Mark Nikolaj Niedermaier Uwe Zeymer Peter Limbourg Thomas Ischinger Klaus Haerten Karl Eugen Hauptmann Enz-Rüdiger von Leitner Wolfgang Kasper Ulrich Tebbe Jochen Senges 《European heart journal》2004,25(17):1550-1558
AIMS: Carotid artery stenting (CAS) for carotid artery stenoses has become an alternative to carotid endarterectomy. However, CAS itself can cause cerebral ischaemic events. Embolic protection devices (PD) promise to reduce the incidence of these events. METHODS AND RESULTS: From July 1996 to March 2003, 1483 patients from 26 hospitals were included in the prospective CAS Registry of the ALKK study group. A PD was used in 668 of 1483 patients (45%). The use of a PD has grown rapidly over the years and reached 100% in 2003. Patients treated with a PD had prior carotid artery dilatation more often (3.5% versus 1%, p < 0.001), a prior myocardial infarction (34% versus 27.4%, p = 0.007) and a history of arterial hypertension (89.9% versus 78.6%, p = 0.007) compared to patients treated without a PD. A thrombus was more often visible in patients treated under distal protection (16.5% versus 8%, p < 0.001). The use of a PD led to a 10-min longer intervention (45 min versus 35 min median, p < 0.001). Patients treated with a PD had a lower rate of ipsilateral stroke (1.7% versus 4.1%, p = 0.007) and a lower rate of all non-fatal strokes and all deaths (2.1% versus 4.9%, p = 0.004) during the hospital stay. This was confirmed by multiple logistic regression analysis (adjusted OR = 0.45, 95% CI: 0.23-0.91, p = 0.026). A similar reduction could be found for symptomatic as well as asymptomatic carotid artery stenoses. CONCLUSION: Since 1996 there has been a steady increase in the use of PDs for CAS, with a 100% use in 2003. The use of a PD may lower the rate of ipsilateral strokes during CAS. 相似文献
8.
9.